Show Summary Details
Page of

Multidrug-resistant Pseudomonas aeruginosa infection in cystic fibrosis 

Multidrug-resistant Pseudomonas aeruginosa infection in cystic fibrosis
Chapter:
Multidrug-resistant Pseudomonas aeruginosa infection in cystic fibrosis
Author(s):

James Hatcher

DOI:
10.1093/med/9780199665754.003.0027
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 08 December 2019

Pseudomonas aeruginosa infection in cystic fibrosis (CF) is common and is associated with significant morbidity and mortality. Antibiotics aimed at Pseudomonas are used to eradicate early infection, suppress chronic infection, and treat acute exacerbations. Treatment options are limited due to increasing resistance and in vitro susceptibility information does not always correlate with in vivo outcomes. A case is presented with chronic Pseudomonas infection and the management and antibiotic choices for the patient during an acute hospital admission discussed, including the role of inhaled antibiotics such as tobramycin.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.